ASCO: Adjuvant Breast Cancer Beckons for Merck/AZ’s Lynparza With OlympiA
A decent 42% reduction in the risk of recurrence in high-risk early-stage BRCA mutated disease should open another new market for the leading PARP inhibitor. Data also hint at a survival benefit to come.
You may also be interested in...
One of two PARP inhibitors approved in breast cancer, Lynparza may have the adjuvant breast indication all to itself for a while. One analyst projects a $1.5bn revenue opportunity for the indication.
AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.
This year’s American Society of Clinical Oncology meeting is set to take place virtually from 4-8 June, and while many abstracts have now been released for this year’s conference, we take a sneak peek at what is still under wraps, with five of the key late-breaking presentations due to be presented at the plenary session, with input from Biomedtracker and Datamonitor Healthcare.